Lomefloxacin compared with trimethoprim for the treatment of women with cystitis.
A prospective, randomised, single-blind study compared the efficacy and safety of the long-acting difluoroquinolone, lomefloxacin, with trimethoprim for the treatment of women with cystitis. Seventy-five patients were treated with either lomefloxacin (400 mg once daily) or trimethoprim (300 mg once daily) for 5 days. Of the 75 patients enrolled, 47 were evaluable for efficacy. All patients treated with lomefloxacin and all but one treated with trimethoprim had a satisfactory clinical response. Twenty-three of 24 patients (96%) treated with lomefloxacin and 22 of 23 (96%) with trimethoprim had a satisfactory bacteriological response. All 75 patients were evaluated for safety. No serious side effects or toxicity were noted and no patients was withdrawn because of an adverse reaction. Both drugs proved highly effective and safe for the treatment of women with cystitis.